Another notable pan-tumor trial evaluating capivasertib is the phase II clinical trial (NCT03310541), which highlighted allele-specific differences in AKT activation and inhibitor sensitivity, reporting an ORR of 33% and stable disease in one of six patients with non-AKT1 E17K mutations [92]. Here, AKT1 is linked to neoplasm.